Abbott eyes Humira tweaks on way to No. 1

Abbott Laboratories has big plans for new forms of Humira, the Wall Street Journal reports, including a long-acting, one-dose-a-month version, in an attempt to keep growing a franchise that is set to top the drug-sales charts beginning next year. Report